Enfusion, Inc. (ENFN) reported $48.05 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 17.3%. EPS of $0.06 for the same period compares to $0.03 a year ago.The reported revenue represents a surprise of +0.80% over the Zacks Consensus Estimate of $47.67 million. With the consensus EPS estimate being $0.04, the EPS surprise was +50.00%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to deter ...

Exhibit 99.1 Disclaimer Forward-Looking Statements Statements we make in this presentation may include statements which are not historical facts and are considered forward- looking within the meaning of Section 27A of the Securities Act of 1933 (Securities Act) and Section 2IE of the Securities Exchange Act of 1934 (Exchange Act), including expectations regarding future financial performance. These forward-looking statements are usually identified by the use of words such as "anticipates," "believes," "esti ...

The best photo for all Investment overview I wrote about Enfusion (NYSE:ENFN) previously with a buy rating as I thought the business would continue to grow, with potential for acceleration given the visible catalysts available. Notably, valuation multiples should start to reflect their true worth when the business starts to generate profits. My recommendation remains buy-rated for ENFN as the growth outlook is still very bright, supported by ENFN's strong track record of execution. 4Q23 earnings ENFN report ...

Enfusion, Inc. (NYSE:ENFN) Q4 2023 Earnings Conference Call March 12, 2024 8:30 AM ET Company Participants Bill Wright - Head, IR Oleg Movchan - CEO Brad Herring - CFO Neal Pawar - COO Conference Call Participants Michael Infante - Morgan Stanley Dylan Becker - William Blair Alexei Gogolev - JPMorgan Natalie Howard - Bank of America Gabriela Borges - Goldman Sachs Operator Good morning, ladies and gentlemen. Thank you for standing by. Welcome to Enfusion's Fourth and Full Year 2023 Earnings Conference Call. ...

Enfusion, Inc. (ENFN) reported $46.49 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 14.7%. EPS of $0.04 for the same period compares to $0.03 a year ago.The reported revenue represents a surprise of +2.04% over the Zacks Consensus Estimate of $45.56 million. With the consensus EPS estimate being $0.06, the EPS surprise was -33.33%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to de ...

Enfusion, Inc. (ENFN) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -33.33%. A quarter ago, it was expected that this company would post earnings of $0.05 per share when it actually produced earnings of $0.04, delivering a surprise of -20%.Over the last four quarters, the company ha ...

Exhibit 99.1 Disclaimer Forward-Looking Statements Statements we make in this presentation may include statements which are not historical facts and are considered forward- looking within the meaning of Section 27A of the Securities Act of 1933 (Securities Act) and Section 2IE of the Securities Exchange Act of 1934 (Exchange Act), including expectations regarding future financial performance. These forward-looking statements are usually identified by the use of words such as "anticipates," "believes," "esti ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Address of principal executive offices) (Zip code) 125 South Clark Street, Suite 750, Chicago, IL 60603 60603 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-40949 ENFUSION ...

NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced it will release its fourth quarter and full year 2023 financial results before the U.S. financial markets open on Tuesday, March 12, 2024. Management will host a conference call and webcast that same morning at 5:30 AM (PT) / 8:30 AM (ET) to discuss the results. To access this call, dial (888) 596-4144. The conference ...

NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, will host an investor day in Fort Lauderdale, Florida on March 19th, 2024. The event will feature presentations from Enfusion’s executive team and provide an overview of Enfusion’s fully integrated investment technology platform, current and future market positioning, and growth outlook over the medium term. The formal presentations ...